NASDAQ:FENC

Fennec Pharmaceuticals Stock Forecast, Price & News

$4.39

-0.25 (-5.39%)

(As of 01/21/2022 12:00 AM ET)

Add

Compare

Today's Range: $4.28
▼
$4.59
50-Day Range: $3.89
▼
$10.01
52-Week Range: $2.90
▼
$5.20

Volume: 68,900 shs
Average Volume: 66,743 shs
Market Capitalization: $114.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: 0.06

30 days | 90 days | 365 days | Advanced Chart

Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc. Common Stock (FENC)
January 14, 2022 | nasdaq.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fennec Pharmaceuticals Inc. - FENC
December 14, 2021 | finance.yahoo.com

RTP drugmaker suffers another regulatory setback
December 1, 2021 | finance.yahoo.com

FENC – Fennec Pharmaceuticals Inc. Investors Who Have Lost More Than $25,000 Are Encouraged To Contact Kehoe Law Firm, P.C. – Securities Class Action Investigation
November 30, 2021 | finance.yahoo.com

Fennec Pharma: FDA Issues CRL Due To Manufacturing Deficiencies - Quick Facts
November 30, 2021 | nasdaq.com

Fennec Shares Plunge as Pedmark Appears Headed for FDA Rejection >FENC
November 29, 2021 | marketwatch.com

Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide
November 29, 2021 | markets.businessinsider.com

Fennec Pharma expects FDA to decline application for hearing loss drug
November 29, 2021 | reuters.com

Fennec does not expect U.S. approval for hearing loss drug, shares slump
November 29, 2021 | reuters.com

Fennec Plunges As FDA Is Expected To Deny Approval For Pedmark Yet Again
November 29, 2021 | nasdaq.com

Are Institutions Heavily Invested In Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Shares?
November 12, 2021 | nasdaq.com

Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FENC
Previous Symbol
CUSIP: N/A
CIK: 1211583
Web: www.fennecpharma.com
Phone: 919-636-4530
Fax: 919-890-0490
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $170 thousand
Price / Sales: 671.77
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.12 per share
Price / Book: 3.92

Profitability

EPS (Most Recent Fiscal Year): ($0.62)
Net Income: $-18.11 million
Net Margins: N/A
Pretax Margin: -9,504.12%
Return on Equity: -67.82%
Return on Assets: -57.01%

Debt

Debt-to-Equity Ratio: 0.26
Current Ratio: 12.90
Quick Ratio: 12.90

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: 3.72
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 26,014,000
Free Float: 23,496,000
Market Cap: $114.20 million
Optionable: Optionable

Company Calendar

Last Earnings: 11/10/2021
Today: 1/22/2022
Next Earnings (Estimated): 3/29/2022
Fiscal Year End: 12/31/2022

MarketRank^™

Overall MarketRank^™

1.73 out of 5 stars

Medical Sector

926th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

140th out of 206 stocks

3.4 Analyst's Opinion

Consensus Rating
Fennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.67, Fennec Pharmaceuticals has a forecasted upside of 188.5% from its current price of $4.39.
Amount of Analyst Coverage
Fennec Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

4.4 Community Rank

Outperform Votes
Fennec Pharmaceuticals has received 175 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Fennec Pharmaceuticals has received 91 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Fennec Pharmaceuticals has received 65.79% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote “Outperform” if you believe FENC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Fennec Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Fennec Pharmaceuticals does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fennec Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.68% of the stock of Fennec Pharmaceuticals is held by insiders.
Percentage Held by Institutions
44.79% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Fennec Pharmaceuticals are expected to decrease in the coming year, from $1.18 to ($0.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fennec Pharmaceuticals is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fennec Pharmaceuticals is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fennec Pharmaceuticals has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

Is Fennec Pharmaceuticals a buy right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals or view top-rated stocks.
How has Fennec Pharmaceuticals' stock been impacted by COVID-19?: Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FENC shares have decreased by 33.8% and is now trading at $4.39.
View which stocks have been most impacted by COVID-19.
When is Fennec Pharmaceuticals' next earnings date?: Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Fennec Pharmaceuticals.
How were Fennec Pharmaceuticals' earnings last quarter?: Fennec Pharmaceuticals Inc (NASDAQ:FENC) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.01.
View Fennec Pharmaceuticals' earnings history.
What price target have analysts set for FENC?: 5 Wall Street analysts have issued 12-month price objectives for Fennec Pharmaceuticals' shares. Their forecasts range from $10.00 to $14.00. On average, they expect Fennec Pharmaceuticals' stock price to reach $12.67 in the next year. This suggests a possible upside of 188.5% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals or view top-rated stocks among Wall Street analysts.
Who are Fennec Pharmaceuticals' key executives?: Fennec Pharmaceuticals' management team includes the following people:
Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
Mr. Mark Gowland, Controller
Mr. Lei Fang, Pres of Pharstat Inc
Ms. Anne McKay, Regulatory Consultant (Age 64)
Who are some of Fennec Pharmaceuticals' key competitors?: Some companies that are related to Fennec Pharmaceuticals include Adaptimmune Therapeutics (ADAP), Omega Therapeutics (OMGA), Finch Therapeutics Group (FNCH), Ikena Oncology (IKNA), Tenaya Therapeutics (TNYA), Talaris Therapeutics (TALS), Athira Pharma (ATHA), BioAtla (BCAB), Tarsus Pharmaceuticals (TARS), Innate Pharma (IPHYF), Gritstone bio (GRTS), Oyster Point Pharma (OYST), Innate Pharma (IPHA), Fusion Pharmaceuticals (FUSN) and Aerie Pharmaceuticals (AERI).
View all of FENC's competitors.
What other stocks do shareholders of Fennec Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).
What is Fennec Pharmaceuticals' stock symbol?: Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."
How do I buy shares of Fennec Pharmaceuticals?: Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fennec Pharmaceuticals' stock price today?: One share of FENC stock can currently be purchased for approximately $4.39.
How much money does Fennec Pharmaceuticals make?: Fennec Pharmaceuticals has a market capitalization of $114.20 million and generates $170 thousand in revenue each year. The company earns $-18.11 million in net income (profit) each year or ($0.62) on an earnings per share basis.
What is Fennec Pharmaceuticals' official website?: The official website for Fennec Pharmaceuticals is www.fennecpharma.com.
Where are Fennec Pharmaceuticals' headquarters?: Fennec Pharmaceuticals is headquartered at PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709.
How can I contact Fennec Pharmaceuticals?: Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.

This page was last updated on 1/22/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Fennec Pharmaceuticals Stock Forecast, Price & News

About Fennec Pharmaceuticals

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

MarketRank™

Overall MarketRank™

3.4 Analyst's Opinion

4.4 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

0.8 Company Ownership

0.0 Earnings and Valuation

Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

Is Fennec Pharmaceuticals a buy right now?

How has Fennec Pharmaceuticals' stock been impacted by COVID-19?

When is Fennec Pharmaceuticals' next earnings date?

How were Fennec Pharmaceuticals' earnings last quarter?

What price target have analysts set for FENC?

Who are Fennec Pharmaceuticals' key executives?

Who are some of Fennec Pharmaceuticals' key competitors?

What other stocks do shareholders of Fennec Pharmaceuticals own?

What is Fennec Pharmaceuticals' stock symbol?

How do I buy shares of Fennec Pharmaceuticals?

What is Fennec Pharmaceuticals' stock price today?

How much money does Fennec Pharmaceuticals make?

What is Fennec Pharmaceuticals' official website?

Where are Fennec Pharmaceuticals' headquarters?

How can I contact Fennec Pharmaceuticals?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™